ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
Dow Jones
44.544,66
-0,75%
Euro vs US Dollar
1,0366
0,04%
Bitcoin
100.855,45
0,19%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Aligos Therapeutics Inc (ALGS) Börsenkurse

Aligos Therapeutics Inc

Aligos Therapeutics Inc (ALGS)

NASDAQ
25,80
2,06
(8,68%)
Geschlossen 02 Februar 10:00PM
Verzögert um 15 Minuten
26,42
0,62
(2,40%)
Nach Börsenschluss: 1:44AM
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
26,42
Gebot
25,27
Fragen
31,76
Volumen
375.065
24,10 Tagesbereich 27,61
6,76 52-Wochen-Bereich 46,80
Marktkapitalisierung
94,792M
Handelsende
23,74
Handelsbeginn
24,35
Letzte Trade
5
@
25.5001
Letzter Handelszeitpunkt
Finanzvolumen
US$ 9.817.967
VWAP
26,1767
Durchschnittliches Volumen (3 Mio.)
505.590
Ausgegebene Aktien
3.587.892
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,05
Gewinn pro Aktie (EPS)
-24,44
Erlöse
15,53M
Nettogewinn
-87,68M

Über Aligos Therapeutics Inc

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's p... Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
www.aligos.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Aligos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALGS. The last closing price for Aligos Therapeutics was US$23,74. Over the last year, Aligos Therapeutics shares have traded in a share price range of US$ 6,76 to US$ 46,80.

Aligos Therapeutics currently has 3.587.892 shares in issue. The market capitalisation of Aligos Therapeutics is US$85,18 million. Aligos Therapeutics has a price to earnings ratio (PE ratio) of -1.05.

ALGS Neueste Nachrichten

Weitere Nachrichten

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving...

13 Dezember 2024
GlobeNewswire Inc.

Aligos Therapeutics to Present at Investor Conferences in December

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through...

26 November 2024
GlobeNewswire Inc.

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...

19 November 2024
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

19 November 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

06 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

06 November 2024
Edgar (US Regulatory)

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient...

06 November 2024
GlobeNewswire Inc.

Form 8-K - Current report

06 November 2024
Edgar (US Regulatory)

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), Aligos a clinical stage biopharmaceutical company focused on improving patient outcomes...

30 Oktober 2024
GlobeNewswire Inc.

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq:...

22 Oktober 2024
GlobeNewswire Inc.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-5.85-18.128292531832.2733.0421.6529252125.20740648CS
4-14.29-35.101940555140.7146.821.6532726433.89273948CS
1216.55167.6798378939.8746.89.680550559027.34261899CS
2613.17599.471498678713.24546.86.7631916122.39224054CS
529.6757.731343283616.7546.86.7635567619.63534586CS
156-43.58-62.257142857170836.7627452529.09046833CS
260-342.08-92.8303934871368.5937.74756.76256381120.17725363CS

ALGS - Frequently Asked Questions (FAQ)

What is the current Aligos Therapeutics share price?
The current share price of Aligos Therapeutics is US$ 26,42
How many Aligos Therapeutics shares are in issue?
Aligos Therapeutics has 3.587.892 shares in issue
What is the market cap of Aligos Therapeutics?
The market capitalisation of Aligos Therapeutics is USD 85,18M
What is the 1 year trading range for Aligos Therapeutics share price?
Aligos Therapeutics has traded in the range of US$ 6,76 to US$ 46,80 during the past year
What is the PE ratio of Aligos Therapeutics?
The price to earnings ratio of Aligos Therapeutics is -1,05
What is the cash to sales ratio of Aligos Therapeutics?
The cash to sales ratio of Aligos Therapeutics is 5,93
What is the reporting currency for Aligos Therapeutics?
Aligos Therapeutics reports financial results in USD
What is the latest annual turnover for Aligos Therapeutics?
The latest annual turnover of Aligos Therapeutics is USD 15,53M
What is the latest annual profit for Aligos Therapeutics?
The latest annual profit of Aligos Therapeutics is USD -87,68M
What is the registered address of Aligos Therapeutics?
The registered address for Aligos Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Aligos Therapeutics website address?
The website address for Aligos Therapeutics is www.aligos.com
Which industry sector does Aligos Therapeutics operate in?
Aligos Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
731,1M
REBNReborn Coffee Inc
US$ 3,31
(63,05%)
55,54M
FCUVFocus Universal Inc
US$ 5,87
(56,62%)
1,73M
SOPASociety Pass Inc
US$ 1,54
(56,50%)
13,87M
CYCNCyclerion Therapeutics Inc
US$ 3,92
(54,33%)
82,57M
ENVBEnveric Biosciences Inc
US$ 2,0899
(-46,41%)
1,57M
NIVFNewGenIvf Group Ltd
US$ 0,1489
(-42,51%)
14,8M
GLSTGlobal Star Acquisition Inc
US$ 8,83
(-39,10%)
23,89k
PRPHProPhase Labs Inc
US$ 0,2633
(-38,02%)
872,46k
SPGCSacks Parente Golf Inc
US$ 0,5601
(-37,86%)
7,27M
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
729,72M
NVDANVIDIA Corporation
US$ 120,07
(-3,67%)
388,54M
RIMEAlgorhythm Holdings Inc
US$ 0,02565
(5,12%)
338,75M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0355
(-11,25%)
236,29M
CLEUChina Liberal Education Holdings Ltd
US$ 0,1938
(30,77%)
234,8M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
ALGS
Aligos Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten